Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis

Conclusion ADA was effective for inducing and maintaining both a clinical response and remission in patients with refractory UC. It remains possible that the concomitant use of IM and a week 8 partial Mayo score of ≤2 may predict the long-term response of ADA.PMID:34121007 | DOI:10.2169/internalmedicine.7279-21

Source: Internal Medicine - June 14, 2021 Category: Internal Medicine Authors: Shinsuke Kumei Toshihiro Sakurai Suketo So Soichi Itaba Hirotada Akiho Shigeo Nakamura Hyonji Kim Masahiro Yamasaki Noritaka Takatsu Ryuichiro Maekawa Ryosuke Sakemi Tatsuyuki Watanabe Michihiko Shibata Keiichiro Kume Ichiro Yoshikawa Yasuhiro Takaki Masa Source Type: research